A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)

Launched by TG THERAPEUTICS, INC. · May 23, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the real-world experience of people with Relapsing Multiple Sclerosis (RMS) who are treated with BRIUMVI® (ublituximab-xiiy). The goal is to understand how safe and effective this treatment is, as well as to learn about the experiences of those receiving it. Researchers are currently looking for participants aged 65 to 74 who have been diagnosed with Multiple Sclerosis but have not yet received BRIUMVI® before the study starts.

To join the trial, participants must not have had any live vaccines in the month before starting BRIUMVI® and must not have any active infections. They also shouldn’t be taking other MS treatments at the same time. If you decide to participate, you'll receive BRIUMVI® during the study, and the team will monitor your health and treatment experience closely. This trial aims to provide valuable insights that could help improve the care and treatment of people living with Multiple Sclerosis.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Confirmed Multiple Sclerosis (MS) diagnosis.
• • 2. Participants who have not received any BRIUMVI® (ublituximab-xiiy) infusion prior to study start. Participants who have been prescribed BRIUMVI® (ublituximab-xiiy) but have not yet received their first infusion on Day 1 of 150 milligrams (mg) can be included.
• Exclusion Criteria:
• • 1. Have received any live or live-attenuated vaccines (including for varicella-zoster virus or measles) within 4 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration or any non-live vaccines within 2 weeks prior to first BRIUMVI® (ublituximab-xiiy) administration.
• • 2. Any active infection (e.g., active Hepatitis B virus \[HBV\])
• • 3. Concurrent participation in any interventional MS trials, or planned concurrent treatment with other Multiple Sclerosis Disease Modifying Therapy (MS DMT) during the study period.